Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

Impact · against what's priced in

Immatics shares are likely to rise following strong Phase 1b data for anzu-cel in metastatic uveal melanoma, particularly the high median shrinkage of 49.6% in liver lesions. The ability to show efficacy in patients who failed prior TCR-based therapies suggests a competitive advantage in a high-unmet-need population.

IMTX+0.80

No priced-in read yet